medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2011, Number 96

<< Back Next >>

Rev Enfer Infec Pediatr 2011; 24.25 (96)

Use of zanamivir in pediatric patients diagnosed with pandemic influenza (AH1N1) in private pediatric practice: first experience in Mexico

Coria-Lorenzo JJ, Toquero-Franco JO, Díaz- Toquero A, Ibarra-Gálvez JM

Language: Spanish
References: 14
Page: 172-177
PDF size: 189.62 Kb.


ABSTRACT

Background: In April 2009, the global alert issued by WHO on the pandemic caused by swine influenza virus H1N1 (SWIV) encouraged physicians of the first, second and third levels of care to update and know about the behavior of this new viral infection. A group of doctors from the Hospital Ángeles Puebla treated a group of pediatric patients with symptoms of pandemic influenza ASwH1N1.
Objective: To describe the results of zanamivir prescription for pediatric patients with influenza H1N1.
Material and methods: Longitudinal, cases, descriptive and observational study. We included 143 patients treated between September 17, 2009 and April 21, residing in the city of Puebla and met the criteria of the NIAID (National Institutes of Allergy and Infectious Diseases). All positive cases (38/143) for influenza rapid test were positive by confirmatory PCR test and were treated within 24 hours of onset of symptoms with pediatric doses of nebulized zanamivir.
Results: fever yielded at 24 hours in 25 patients (66%) and 13 patients (34%) at 48 hours after initiation of treatment. Only one patient required hospitalization for surveillance. There were no deaths or systemic complications in any of the cases treated. These results are due to the timely implementation of nebulized zanamivir.


REFERENCES

  1. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, et al. Pandemic potential of a strain of Influenza A (H1N1): early findings. Science Express Report. www.sciencexpress.org/11 May 2009;1/10.1126/ science.1176062.

  2. Serrano AS, Pérez VR, Nava MF, Villa MG. Experiencia en el Hospital Infantil de México Federico Gómez ante la epidemia por el virus FluA/SWH1N1: Reporte preliminar. Bol Med Hosp Inf Mex 2009;66:301-305.

  3. http://www.who.int/csr/disease/swineflu/

  4. National Institutes of Health, NIAID National Institutes of Allergy and Infectious Diseases 2008: www.niaid.nih.gov

  5. Ayora-Talavera G. Influenza: Historia de una enfermedad. Rev Biomed 1999; 10:57-61.

  6. Truells J. La gripe del cerdo (1976): cuando el pánico y la política toman las decisiones. Vacunas 2007;8(2):119-125.

  7. Newman L. As Novel H1N1 influenza reaches pandemic level, public health preparedeness efforts build. Medscapr Public Health & Prevention. www.medscape.com. 06/Junio/2009:1-4.

  8. Boletín Epidemiológico de la Secretaría de Salud, DGE. Junio, 2009.

  9. Interim Guidance on Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection and Close Contacts. CDC, April 29, 2009.

  10. Acciones para mitigar la intensificación de la trasmisión de influenza estacional en el país. Acciones básicas ante la intensificación de la transmisión de influenza. SS. Boletin Influenza. pdf 2 19/04/09 09:07 p.m. Abril 2009.

  11. Comunicación oral. Bradley John. Pandemic H1N1, 45th Annual Pediatric Postgraduate Course: “Perspectives in Pediatrics”, Miami Children`s Hospital February 22 2010.

  12. Chowell G, Bertozzi SM, Colchero A, Lopez-Gatell H, et al. Severe Respiratory Disease Concurrent with the Circulation of H1N1 Influenza. N Engl J Med 2009;361:674-679.

  13. Questions & Answers: Antiviral Drugs for Seasonal Flu. CDC, December 19. 2008.

  14. Interim Guidance on Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection and Close Contacts. CDC, April 29. 2009.




2020     |     www.medigraphic.com